Ismail E, Kornovski Y
Akush Ginekol (Sofiia). 2015;54(6):16-23.
The cervical cancer is one of the most common malignancies. Worldwide 500,000 women a year become ill from cervical cancer. The aim of the study was to establish the role of adjuvant radiotherapy in patients with IB1 cervical cancer in terms of disease free survival. Between 2002-2012, 132 patients diagnosed as IB1 stage according to FIGO criteria were enrolled in the study. Depending on the administered therapy the patients were divided into two groups--Group 1-93 patients were treated surgically and with adjuvant radiotherapy and Group 2--39 patients were treated surgically without adjuvant radiotherapy Surgery was radical hysterectomy class III and pelvic or paraaortic lymph node dissection(in cases of bulky paraaortic nodes), and adjuvant RT-telegamma therapy(TGT) in dose 52 Gy. The frequency of recurrence in a Group I (surgery and TGT) is 9.7%. Tree and five years disease free survival (DFS) is 88%. The frequency of recurrence in a Group 2 (surgery without TGT) is 25.6%. Tree and five years DFS respectively are 70% and 65%. In an analysis of oncological results establish that adjuvant TGT after surgery significantly increases DFS. On the other hand the addition of adjuvant TGT increases the patients morbidity Therefore should determine which are the risk factors for the occurrence of relapses and select group of patients who would benefit from adjuvant TGT and the risk of complications in them would be justified.
宫颈癌是最常见的恶性肿瘤之一。全球每年有50万女性罹患宫颈癌。本研究的目的是确定辅助放疗在IB1期宫颈癌患者无病生存方面的作用。2002年至2012年期间，132例根据国际妇产科联盟（FIGO）标准诊断为IB1期的患者纳入本研究。根据所接受的治疗，患者被分为两组——第1组，93例患者接受手术及辅助放疗；第2组，39例患者仅接受手术未行辅助放疗。手术为III级根治性子宫切除术及盆腔或腹主动脉旁淋巴结清扫术（腹主动脉旁淋巴结肿大时），辅助放疗采用远距离γ射线治疗（TGT），剂量为52 Gy。第1组（手术加TGT）的复发率为9.7%。3年和5年无病生存率（DFS）为88%。第2组（手术未加TGT）的复发率为25.6%。3年和5年DFS分别为70%和65%。在肿瘤学结果分析中发现，术后辅助TGT显著提高DFS。另一方面，辅助TGT的加入增加了患者的发病率。因此，应确定哪些是复发的危险因素，并选择能从辅助TGT中获益且并发症风险合理的患者群体。
